The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the

8 Best Healthcare AI Stocks to Buy According to Analysts.

On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 update expected on May 11, 2026.

Just earlier in the month of April, JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy rating and $11 price target on the shares. The firm has said that AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody discovery platform has advanced 19 molecules into clinical development across both internal and partnered programs spanning multiple therapeutic areas, with its capabilities “best illustrated” through its collaboration with Eli Lilly.

AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based therapies targeting diseases with unmet medical needs.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.